NASDAQ$TLPH
AcelRx Pharmaceuticals Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported third quarter financial results, highlighted by revenue growth and strategic collaborations.
AcelRx Pharmaceuticals reported a net revenue of $1.4 million for the third quarter of 2020, with product sales contributing $1.3 million, a significant increase from the previous quarter. The company's net loss was $8.9 million, or $0.10 per share. Key achievements included a collaboration with Zimmer Biomet and expansion of DSUVIA's availability to the U.S. Department of Defense.
- Third quarter product sales reached $1.3 million, a substantial increase from $0.3 million in the second quarter.
- Entered into a distribution agreement with Zimmer Biomet to market DSUVIA in the dental and oral surgery markets.
- DSUVIA was added to the U.S. Department of Defense Joint Deployment Formulary.
- U.S. Army awarded AcelRx with an initial contract of up to $3.6 million over four years for DSUVIA purchase.
Headline financials
Revenue & EPS history
AcelRx · Revenue · Quarterly
$1.37M
Forward guidance
AcelRx anticipates continued progress within the Department of Defense and expects initial ordering of DSUVIA for deployed troops in the fourth quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2020
-2.7%
Avg return
Earnings day
-3.4%
Avg return
5 days after
+1.1%
Avg return
30 days after
32%
20 / 62 earnings
Positive
+23.5%
Q4 2017
Best reaction
-46.9%
Q4 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.7% | -7.0% | — | |
| Q3 2025 | -18.6% | +3.9% | -7.8% | |
| Q2 2025 | +0.0% | +14.0% | +118.6% | |
| Q1 2025 | -3.9% | +2.0% | -3.9% | |
| Q4 2024 | +6.0% | +2.0% | +2.0% | |
| Q3 2024 | -2.2% | -25.3% | -28.6% | |
| Q2 2024 | -5.5% | +2.2% | -1.1% | |
| Q1 2024 | -1.0% | +4.9% | -4.9% | |
| Q4 2025 | +0.0% | -1.9% | +1.9% | |
| Q4 2023 | +1.6% | -12.0% | -4.0% | |
| Q3 2023 | -9.7% | -11.5% | +40.4% | |
| Q2 2023 | -7.4% | -18.9% | -8.4% | |
| Q1 2023 | +14.5% | +14.5% | +79.7% | |
| Q4 2022 | -8.3% | -16.7% | -6.9% | |
| Q3 2022 | +22.3% | +16.0% | +22.3% | |
| Q2 2022 | +12.5% | +33.3% | +16.7% | |
| Q1 2022 | +4.8% | +23.8% | -4.8% | |
| Q4 2021 | -22.7% | -29.5% | -38.6% | |
| Q3 2021 | -10.1% | -8.9% | -34.2% | |
| Q2 2021 | -20.5% | -10.3% | -12.8% | |
| Q1 2021 | +11.2% | +9.6% | +18.3% | |
| Q4 2020 | -16.2% | -21.6% | -97.0% | |
| Q3 2020 | -20.8% | -21.3% | -16.9% | |
| Q2 2020 | -7.6% | -0.8% | -12.9% | |
| Q1 2020 | -1.3% | -9.7% | -11.0% | |
| Q4 2019 | -7.8% | -18.4% | +25.2% | |
| Q3 2019 | -1.5% | -12.3% | -7.9% | |
| Q2 2019 | -5.8% | -7.4% | -4.1% | |
| Q1 2019 | -10.7% | -10.1% | -34.8% | |
| Q4 2018 | -9.4% | -14.4% | -4.4% | |
| Q3 2018 | +2.9% | -14.5% | -18.8% | |
| Q2 2018 | +5.7% | +7.5% | +17.0% | |
| Q1 2018 | +0.0% | +2.0% | +48.0% | |
| Q4 2017 | +23.5% | +26.5% | +29.4% | |
| Q3 2017 | +1.5% | -5.1% | +7.7% | |
| Q2 2017 | -24.4% | -25.6% | -15.4% | |
| Q1 2017 | -3.7% | -7.4% | -16.7% | |
| Q4 2016 | +11.5% | +3.3% | +3.3% | |
| Q3 2016 | -3.6% | -7.1% | +1.8% | |
| Q2 2016 | +19.8% | +17.8% | +5.9% | |
| Q1 2016 | -6.2% | — | — | |
| Q4 2015 | -8.7% | — | — | |
| Q3 2015 | +13.5% | — | — | |
| Q2 2015 | +8.0% | — | — | |
| Q1 2015 | -24.6% | — | — | |
| Q4 2014 | -46.9% | — | — | |
| Q3 2014 | +14.7% | — | — | |
| Q2 2014 | -5.1% | — | — | |
| Q1 2014 | -5.6% | — | — | |
| Q4 2013 | +7.0% | — | — | |
| Q3 2013 | -0.4% | — | — | |
| Q2 2013 | -12.9% | — | — | |
| Q1 2013 | -3.6% | — | — | |
| Q4 2012 | -5.0% | — | — | |
| Q3 2012 | -5.8% | — | — | |
| Q2 2012 | -2.3% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -5.9% | — | — | |
| Q3 2011 | -0.7% | — | — | |
| Q2 2011 | +2.8% | — | — | |
| Q1 2011 | +5.1% | — | — | |
| Q4 2010 | -3.1% | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro